Drug Development

Boehringer Ingelheim axes 725 jobs in U.S. reorganization

Boehringer Ingelheim is axing 725 positions in the U.S. as part of a broad restructuring of the company.

In a statement sent to Endpoints, the pharma company noted that some of the staffers affected could wind up in other jobs at Boehringer. A spokesperson did not provide a breakdown on what kind of jobs — administrative, sales or R&D — are involved in the cuts.

Following a careful examination of our human pharmaceuticals business, we made the difficult decision to eliminate approximately 725 positions in the U.S., including approximately 50 in the state of Connecticut,” the company stated. “Many of the people impacted will continue to have the opportunity to pursue new roles within the Company.  The actions we are taking now will help us reinvent the way we serve the needs of our patients, and enable us to continue to make significant investments in Research and Development to continue to identify new medical breakthroughs.  We are sympathetic to the impact this decision may have on Boehringer Ingelheim employees and their families.  We are committed to treating all employees with dignity, respect and sensitivity. We will support affected employees in a number of ways, including severance, outplacement services, and identifying other employment opportunities within the Boehringer Ingelheim network, as appropriate.

Earlier in the week Boehringer announced plans to swap its consumer healthcare business for Sanofi’s animal health group, a multibillion dollar deal.

Boehringer has been discussing restructuring for months now. A company spokesperson told reporters in Connecticut – where it employs more than 2,000 people – that Boehringer was planning an unspecified number of job cuts as it sought to make itself over into a more “sustainable” organization.

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017